Tumor ablation device and related systems and methods

Information

  • Patent Grant
  • 11510723
  • Patent Number
    11,510,723
  • Date Filed
    Thursday, November 7, 2019
    4 years ago
  • Date Issued
    Tuesday, November 29, 2022
    a year ago
Abstract
Tumor ablation devices and related systems and methods are disclosed. Some tumor ablation devices include an RF energy delivery probe with two conductors and one or more thermocouples. The thermocouple measures a temperature at a location on one of the conductors. A generator can produce a current to be conducted between the first conductor and the second conductor via tissue within a desired ablation region. The ablation regions created by the RF energy delivery probe are symmetric about poles of the first conductor and the second conductor. A distal portion of the RF energy delivery probe may articulate, enabling a user to position the RF energy delivery probe in a proper position to ablate the tumor. The thermocouples may be disposed on a flexible or wired thermocouple circuit that is disposed between insulators.
Description
TECHNICAL FIELD

The present disclosure relates generally to the field of medical devices. More particularly, some embodiments relate to spinal tumor ablation devices and related systems and methods. In some embodiments, the tumor ablation devices may be used to treat tumors or lesions in a patient's vertebra.





BRIEF DESCRIPTION OF THE DRAWINGS

The written disclosure herein describes illustrative embodiments that are non-limiting and non-exhaustive. Reference is made to certain of such illustrative embodiments that are depicted in the figures, in which:



FIG. 1 is a perspective view of a tumor ablation system that includes a base unit, a remote, and a medical device.



FIG. 2A is a side view of a RF (radiofrequency) energy delivery probe of the medical device of FIG. 1.



FIG. 2B is a cross-sectional view of the distal portion of the RF energy delivery probe of FIG. 2A.



FIG. 2C is a side view of a RF (radiofrequency) energy delivery probe according to another embodiment.



FIG. 2D is a cross-sectional view of the distal portion of the RF energy delivery probe of FIG. 2C.



FIG. 3A is a schematic representation of a first exemplary ablation zone created by a RF energy delivery probe.



FIG. 3B is a schematic representation of a second exemplary ablation zone created by the RF energy delivery probe of FIG. 3A.



FIG. 3C is a schematic representation of a third exemplary ablation zone created by the RF energy delivery probe of FIG. 3A.



FIG. 3D is a schematic representation of a fourth exemplary ablation zone created by the RF energy delivery probe of FIG. 3A.



FIG. 4A is a schematic representation of the RF energy delivery probe of FIG. 1 being inserted into a vertebral body of a patient to treat a tumor or lesion using unipediclular vertebral access.



FIG. 4B is a schematic representation of the RF energy delivery probe of FIG. 1 delivering energy to ablate the tumor or lesion shown with a portion of the tumor or lesion ablated.



FIG. 4C is a schematic representation of dead tissue of the ablated tumor or lesion with the RF energy delivery probe removed from the vertebral body.



FIG. 5 is a perspective view of a tumor ablation system that includes a base unit, a remote, and a plurality of medical devices.



FIG. 6A is a schematic representation of two RF energy delivery probes being inserted into a vertebral body of a patient to treat a tumor or lesion using bipedicle vertebral access.



FIG. 6B is a schematic representation of two RF energy delivery probes delivering energy to ablate the tumor or lesion with a portion of the tumor or lesion ablated.



FIG. 6C is a schematic representation of dead tissue of the ablated tumor or lesion with two RF energy delivery probes removed from the vertebral body.



FIG. 7 is a schematic representation of a flexible or wired thermocouple circuit for the plurality of thermocouples.



FIG. 8 is diagram of a circuit of the medical device.



FIG. 9A is a side view of a portion of a RF (radiofrequency) energy delivery probe of the medical device of FIG. 1 in a straight configuration.



FIG. 9B is a side view of a portion of the RF (radiofrequency) energy delivery probe of FIG. 9A in an articulated configuration.



FIG. 9C is a side view of a portion of the RF (radiofrequency) energy delivery probe of FIG. 9A in a hyperextended configuration.





DETAILED DESCRIPTION

Tumor ablation devices can be used to treat a tumor in a vertebra or other bones, such as the long bones of a patient. For example, in some embodiments, a distal end of a tumor ablation device may be inserted into a vertebra of a patient. Once the distal end of the tumor ablation device is inserted into the vertebra of the patient, an articulating distal portion of the tumor ablation device may be manipulated to position the tumor ablation device at a desired location within a tumor of the patient. The tumor ablation device may then be activated. Activation of the tumor ablation device may cause an electrical current (e.g., a radiofrequency current) to be applied to ablate tissue, such as the tumor. For instance, radiofrequency current may pass between a first electrode and a second electrode of the tumor ablation device. As the electrical current passes between the first electrode and the second electrode, the current may pass through tissue of the patient, thereby heating (and potentially killing) the adjacent tissue (e.g., tumor cells). The tumor ablation device may comprise one or more temperature sensors which may be used to measure the temperature of the heated tissue adjacent to the tumor ablation device. Based on the information obtained from the one or more temperature sensors, the duration, position, and/or magnitude of the delivered thermal energy may be tailored to ablate tumor tissue within a desired region of the tumor while avoiding the delivery of damaging amounts of thermal energy to healthy tissue. In some embodiments, once the tumor has been treated with thermal energy (e.g., converted radiofrequency energy), a cement may be delivered through with a different device to stabilize the vertebra of the patient.


The components of the embodiments as generally described and illustrated in the figures herein can be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of various embodiments, as represented in the figures, is not intended to limit the scope of the present disclosure, but is merely representative of various embodiments. While various aspects of the embodiments are presented in drawings, the drawings are not necessarily drawn to scale unless specifically indicated.


The phrase “coupled to” is broad enough to refer to any suitable coupling or other form of interaction between two or more entities. Two components may be coupled to each other even though they are not in direct contact with each other. For example, two components may be coupled to one another through an intermediate component. The phrases “attached to” or “attached directly to” refer to interaction between two or more entities that are in direct contact with each other and/or are separated from each other only by a fastener of any suitable variety (e.g., an adhesive).


The terms “proximal” and “distal” are opposite directional terms. For example, the distal end of a device or component is the end of the component that is furthest from the practitioner during ordinary use. The proximal end refers to the opposite end, or the end nearest the practitioner during ordinary use.



FIG. 1 illustrates a tumor ablation system 100 for use in one or more medical procedures, such as procedures to treat a spinal tumor in one or more vertebral bodies of a patient. The tumor ablation system 100 however is not limited to treating spinal tumors in vertebral bodies, but may be used to treat tumors in various other locations in the body, such as the hip, pelvis, or other long bones. The tumor ablation system 100 may comprise a base unit 200, one or more medical devices 400 (or portions thereof) or medical device assemblies for use in a tumor ablation procedure, and a remote 300 that may enable a user to control energy delivery to the medical device 400, or other aspects of the medical device 400.


The base unit 200 may comprise a housing 210 that may house one or more power supplies (e.g., a radiofrequency (“RF”) generator) that provides RF energy to a RF energy delivery probe 410 of the medical device 400. The base unit 200 may further comprise ports 220, 230, 240 that couple the medical devices 400 and the remote 300 to the base unit 200. The base unit 200 of FIG. 1 may include two power supplies (not shown) disposed in the housing 210. In the illustrated embodiment, one of the power supplies may correspond to port 220 and the other power supply may correspond to port 240. In other words, in some embodiments, each port 220, 240 may be electrically coupled to, and powered by, an independent power supply.


In some embodiments, the remote 300 may include a cable 310 and plug 312 that are configured to couple the remote 300 to the base unit 200 via port 230. This coupling may be configured to enable communication between the remote 300 and the base unit 200. In some embodiments, the port 230 may be a wireless port that wirelessly connects with the remote 300. The remote 300 may include a plurality of toggle buttons. The illustrated remote 300 of FIG. 1 illustrates two buttons 320 and 340. In the illustrated embodiment, toggle button 320 is configured to correspond with port 220 and a first power supply (RF generator) disposed in the housing 210 and button 340 is configured to correspond with port 240 and a second power supply (RF generator) disposed in the housing 210. Again, the two power supplies disposed in the housing 210 may be independent of each other. The toggle button 320 may thus be used toggle off and on the power supply (RF generator) corresponding to port 220 and thus toggle off and on energy delivery to a medical device coupled to port 220. Similarly, toggle button 340 may be configured to toggle off and on the delivery of energy to a medical device coupled to port 240.


The base unit 200 may further include a display 250 to display a user interface. The user interface may enable configuration of parameters, setting of preferences, and the like by a physician or other medical professional for the tumor ablation procedure. The user interface may further display a current state of the tumor ablation procedure.


The tumor ablation system 100 may further include one or more medical devices 400 for performing a tissue ablation. FIG. 1 illustrates a single medical device 400 that may be used for single pedicle (unipedicular) vertebral access to treat a tumor or lesion. However, the tumor ablation system 100 may include more than one medical device 400. For example, FIG. 5 illustrates a tumor ablation system 100 with two medical devices 400 and 400′ for performing a two pedicle (bipedicular) vertebral access to treat tumors or lesions.


In the illustrated embodiment, the medical device 400 includes, among other elements, an RF energy delivery probe 410 that includes a first or outer tubular conductor 420, a first or outer tubular insulator 430, a second or inner tubular insulator 440 (not shown in FIG. 1, see FIG. 2B), and a second or inner tubular conductor 450. The RF energy delivery probe 410 may extend from a proximal end 402 to a distal end 401.


The medical device 400 may further include a housing 460 and a cable 472 and plug 474 that is configured to couple the medical device 400 to the base unit 200 to enable communication between the medical device 400 and the base unit 200 and to provide electrical energy to the RF energy delivery probe 410. The base unit 200 may include an extension cable 222 and plug 224 that couples to port 220 or 240 and may extend the range of the RF energy delivery probe 410. In some embodiments, the cable and plug 474 may couple directly to port 220 or 240 without the use of the extension cable 222. As discussed above, each port 220 and 240 correspond with an independent power supply and medical device 400 may be coupled to either port 220 or 240 to access a power supply.


In the illustrated embodiment of FIG. 1, the tumor ablation system 100 is shown comprising a single medical device 400. The tumor ablation system 100 may include a plurality of identifying features that signify to a user which port (220 or 240) to which the medical device 400 is coupled. Systems within the scope of this disclosure may have any combination of the identifying features discussed below.


As detailed below, one or more portions of the medical device 400 or related components may have an indicator light or other feature that identifies the port (220 or 240) to which the medical device 400 is coupled. For example, the plug 474 may include a light 476 (e.g. LED) that lights up when the plug is coupled to either of the ports 220 and 240. For example, if the medical device 400 is coupled to port 220 the light 476 may light up a first color (e.g. blue). If the medical device 400 is coupled to port 240 the light 476 may light up a second color (e.g. white). The light 476 may be a ring that extends around the circumference of the plug 474.


Another identifying feature may be a light 478 (e.g. LED) disposed along the length of the cable 472. The light 478 of the cable 472 may light a first color (e.g. blue) when the medical device 400 is coupled to port 220 and may light up a second color (e.g. white) when the medical device 400 is coupled to port 240.


Similar identifying features may be disposed on the extension cable 222 and plug 224. For example, the plug 224 may include a light 226 (e.g. LED) that may light up a first color (e.g. blue) when the extension cable 222 and plug 224 are coupled to the port 220 and/or a medical device and may light up a second color (e.g. white) when the extension cable 222 and plug 224 are coupled to the port 240 and/or a medical device. The light 226 may be a ring that extends around the circumference of the plug 224. The cable 222 may include a light 228 that is disposed along the length of the extension cable 222 and the light 228 may light up a first color (e.g. blue) when cable 222 and plug 224 are coupled to the port 220 and/or a medical device and a second color (e.g. white) when the cable 222 and plug 224 are coupled to the port 240 and/or a medical device.


Another identifying feature may be a light 462 (e.g. LED) disposed on the housing 460 of the medical device 400. The light 462 of the housing 460 may light a first color (e.g. blue) when the medical device 400 is coupled to port 220 and may light up a second color (e.g. white) when the medical device 400 is coupled to port 240.


Another identifying feature may be disposed on the remote 300. The remote 300 may include lights that distinguish between which toggle button 320 and 340 correspond with each port 220 and 240. For example, toggle button 320 may include a light 322 (e.g. LED) that lights up a first color (e.g. blue) when the remote is coupled to or wirelessly connected to port 230. Toggle button 340 may include a light 342 (e.g. LED) that lights up a first color (e.g. white) when the remote 300 is coupled to or wirelessly connected to port 230. Unlike the other identifying features, the toggle buttons 320 and 340 do not alternate between colors but are color specific to the corresponding port. Accordingly, the user may always know which toggle button 320 and 340 corresponds to which port 220 and 240.


Again, the plurality of identifying features may be independent of the other identifying features or they may be in a number of different combinations. For example, in one embodiment, one of the lights 476, 478, 226, 228, and 462 may be used as the only identifying feature. In another embodiment, light 476 of the plug 474 may work in conjunction with the light 462 of the housing 460. A plurality of different combinations may be used in an attempt to help a physician identify which medical device is coupled to which port 220 and 240.


The base unit 200 may further include a plurality of speakers 260. The speakers 260 enable the base unit 200 to provide audible indicators to the user. For example, when a medical device is turned on and is coupled to port 220 and ablating, the base unit 200 may give a first audible indicator. If a second medical device is turned on and is coupled to port 240 and ablating, the base unit 200 may give a second audible indicator. The audible indicators are different from each other and the user would be able to know by sound if one or two medical devices are currently ablating.



FIGS. 2A-2B illustrate a probe of the medical device 400 in greater detail. FIG. 2A illustrates a side view of the RF energy delivery probe 410, and FIG. 2B illustrates a detailed cross-sectional view of the distal portion of the RF energy delivery probe 410. The RF energy delivery probe 410 may have a first pole or RF+ pole and a second pole, return pole, or RF− pole, the first tubular insulator 430, the second tubular insulator 440, and a primary insulator, or bushing insulator 432 that is disposed between the poles and may act as a bushing.


Though various elements of the embodiment of FIGS. 2A and 2B are referenced as “tubular” (e.g. the first tubular conductor 420, first tubular insulator 430, second tubular insulator 440, and second tubular conductor 450), other geometries of these elements are within the scope of this disclosure. That is, one or more of these elements may be configured with a non-tubular geometry in some embodiments. Further, tubular elements with various cross-sectional shapes, including round, square, rectangular, triangular, polygonal, and so forth are likewise within the scope of this disclosure. Additionally, tubular elements wherein the cross-sectional geometry or size varies along the length of the tubular element are within the scope of this disclosure.


The first tubular conductor 420 may be a metallic tube that extends from a proximal anchor (e.g., a metallic anchor) to an open distal end. The first tubular conductor 420 may act as the second pole (RF−). In some embodiments, a complimentary tubular conductor 421 may be disposed within the first tubular conductor 420. The complimentary tubular conductor may be metallic and may be physically and electrically connected to the first tubular conductor 420.


The first tubular insulator 430 may be at least partially disposed within the first tubular conductor 420. For example, the first tubular insulator 430 may extend through the first tubular conductor 420. More particularly, in some embodiments, the first tubular insulator 430 extends through the first tubular conductor 420 such that a proximal end of the first tubular insulator 430 is proximal of the first tubular conductor 420 and a distal end of the first tubular insulator 430 is proximal of the first tubular conductor 420. The first tubular insulator 430 and the second tubular insulator 440 may be made from any suitable insulating material, such as polymeric insulating materials. Examples of suitable polymeric insulating materials include polyimide, polycarbonate, polyetheretherketone (PEEK), and polyether block amides (e.g., PEBAX®). The first tubular insulator 430 may extend past the open of the first conductor 420 and may act as the primary insulator, or bushing insulator 432, e.g., bushing, between the first pole or RF+ pole and the second pole, return pole, or RF− pole. That is, the first tubular insulator 430 may extend a sufficient distance to function as an insulator along the portion of the exemplary embodiment where the bushing insulator 432 is disposed. In this way the first tubular insulator 430 may take the place of the bushing insulator 432, such that there is no separate element defining the bushing insulator 432. Additionally, in some embodiments, the first tubular insulator 430 may extend along the device and comprise an enlarged section that defines the bushing insulator 432. Thus, the first tubular insulator 430 and bushing insulator 432 may be a single part and may or may not have the same cross-sectional geometry and/or size. In other embodiments, the bushing insulator 432 may be a separate component from the first tubular insulator 430. In such a case, materials such as ceramics (Zirconia) may be considered.


The second tubular insulator 440 may be disposed within the first tubular insulator 430. For example, the second tubular insulator 440 may extend through the first tubular insulator 430. More particularly, in some embodiments, the second tubular insulator 440 extends through the first tubular insulator 430 such that a proximal end of the second tubular insulator 440 is proximal of the first tubular insulator 430 and a distal end of the second tubular insulator 440 is in line with the distal end of the first tubular insulator 430. The second tubular insulator 440 may be made from any suitable insulating material, such as polymeric insulating materials. Examples of suitable polymeric insulating materials include polyimide, polyetheretherketone (PEEK), and polyether block amides (e.g., PEBAX®). In some embodiments, the second tubular insulator 440 may act as the primary insulator or bushing insulator 432, e.g., bushing, between the first pole or RF+ pole and the second pole, return pole, or RF− pole. That is, as with the first tubular insulator 430, the second tubular insulator 440 may extend and form the bushing insulator 432 or may be a separate component from the bushing insulator 432.


The second tubular conductor 450 may be a metallic tube that extends from a proximal end (e.g., a metallic anchor) to a distal end. In some embodiments, the second tubular conductor 450 is rigid (or is rigid along most of its length). The second tubular conductor 450 may be at least partially disposed within the second tubular insulator 440. For example, the second tubular conductor 450 may extend through the second tubular insulator 440 such that a distal portion 452 of the second tubular conductor 450 is disposed distal of the first tubular conductor 420, the first tubular insulator 430, and the second tubular insulator 440. In some embodiments, the distal portion 452 of the second tubular conductor 450 that is disposed distal of the first tubular insulator 430 is longitudinally offset from the first tubular conductor 420 by the longitudinal length of the bushing insulator 432. The bushing insulator 432 may have a length A2 of between 0.1 cm and 0.5 cm. Stated differently, the gap between the distal portion 452 the second tubular conductor 450 and the distal end of the first tubular conductor 420 may be between 0.3 cm and 1.0 cm when the distal portion 452 is in a non-deployed or non-extended configuration, as further detailed below.


The distal portion 452 of the second tubular conductor 450 may act as the first probe electrode (RF+). The second tubular conductor 450 may extend and retract relative to the first tubular conductor 420. In some embodiments, the second tubular conductor 450 may extend and retract axially up to 8 mm, as shown by arrow A1. In some embodiments, the RF energy delivery probe 410 may extend and retract up to 5 mm. In some embodiments, the RF energy delivery probe 410 may extend and retract up to 1 mm. The axial movement of the RF energy delivery probe 410 may be controlled by the physician or by another medical professional and may be displayed on the display 250. The axial movement of the second tubular conductor 450 relative to the first tubular conductor 420 creates a continuous range of distances between the first tubular conductor 420 and the second tubular conductor 450. As discussed later, the extension and retraction of the second tubular conductor 450 relative to the first tubular conductor 420 affects the size of the ablation zones created by the RF energy delivery probe 410.


The RF energy delivery probe 410 may further comprise a plurality of thermocouples. In some embodiments, a distal thermocouple 454 may be disposed within the distal portion 452 of the second tubular conductor 450. The distal thermocouple 454 may be disposed near, or directly at, the maximum distal tip of the RF energy delivery probe 410 (meaning the distal-most point on the distal end 401 of the RF energy delivery probe 410). The distal thermocouple 454 may measure the temperature at the distal end 401 of the RF energy delivery probe 410. The temperature measured by the distal thermocouple 454 may be used for physician's reference and/or by a generator algorithm.


The RF energy delivery probe 410 may further comprise a plurality of thermocouples that are disposed proximal to the distal thermocouple 454. The illustrated embodiment of FIGS. 2A-2B illustrates four thermocouples that are proximal to the distal thermocouple 454. The thermocouples may be evenly spaced apart. A first proximal thermocouple 424 may be 5 mm back from the center of an ablation zone. A second proximal thermocouple 425 may be 10 mm back from the center of the ablation zone. A third proximal thermocouple 426 may be 15 mm back from the center of the ablation zone. A fourth proximal thermocouple 427 may be 20 mm back from the center of the ablation zone. In some embodiments, the fourth proximal thermocouple 427 may be 17.5 mm back from the center of the ablation zone. The thermocouples 424, 425, 426, 427 may be disposed between the first tubular insulator 430 and the second tubular insulator 440. Further, more or fewer thermocouples, positioned at different relative positions are also within the scope of this disclosure. For example, the thermocouples may be positioned at 5 mm intervals as described above or at 1 mm, 2 mm, 3 mm, 4 mm, or other intervals. Spacing wherein the offset between adjacent thermocouples is not constant along the plurality of thermocouples is also within the scope of this disclosure.


The temperatures measured by the proximal thermocouples 424, 425, 426, 427 and the temperature measured by the distal thermocouple 454 may be used for the physician's reference and/or may be employed by a generator algorithm. The algorithm may use the detected temperatures to create symmetric ablation zones that reach a predetermined temperature or thermal dose to ablate or kill the targeted tumor or lesions. Thermal dose is a function of temperature and exposure time.


In some embodiments, the first tubular conductor 420 is rigid (or is rigid along most of its length). In some embodiments, a distal portion of the first tubular conductor 420 includes a plurality of slots 422 proximal to the open distal end and the proximal thermocouples 424, 425, 426, and 427. The proximal thermocouples 424, 425, 426, and 427 and the distal thermocouple 454 are disposed on a rigid and straight section 414 of the RF energy delivery probe 410. The rigid and straight section 414 may be configured to enable the RF energy delivery probe 410 to create symmetric ablation regions. The slots 422 may be perpendicular or angled relative to the primary axis of the first tubular conductor 420. In other embodiments, the first tubular conductor 420 lacks a plurality of slots 422. Other geometries of the slots 422 not specifically described herein fall within the scope of the disclosure.


The slots 422 may enable the distal portion 412 of the RF energy delivery probe 410 to articulate. In some instances, articulation of the distal portion 412 of the RF energy delivery probe 410 may facilitate placement of the distal portion 412 of the RF energy delivery probe 410 at a desired location for ablation. Stated differently, the RF energy delivery probe 410 may have an active steering capability that enables navigation to and within a tumor. In some instances, articulation of the distal portion 412 of the RF energy delivery probe 410 may, additionally or alternatively, mechanically displace tissue (e.g., tumor cells) within the vertebra of the patient. For example, the RF energy delivery probe 410 may function as an articulating osteotome that enables site-specific cavity creation. Stated differently, the articulating distal portion 412 of the RF energy delivery probe 410 may be robust enough to facilitate navigation through hard tissue of a patient. The practitioner may be able to articulate a distal portion 412 of the RF energy delivery probe 410 such that the distal portion 412 transitions from a linear configuration to a non-linear configuration. Articulation of the distal portion 412 may be similar to articulation of the medical device described in U.S. patent application Ser. No. 15/822,864, filed Nov. 27, 2017, hereby incorporated by reference in its entirety.


In some embodiments, the articulation of the RF energy delivery probe 410 may be displayed on the display 250. Accordingly, the user may be able to see the extent of articulation during the procedure.



FIGS. 2C-2D illustrate an alternative embodiment of the RF energy delivery probe 410′ that include an articulating portion with a plurality of slots 422′ that are adjacent to the open distal end and that corresponds with the proximal thermocouples 424′, 425′, 426′, and 427′. The location of the articulating portion enables the RF energy delivery probe 410′ to create a variety of different of ablation regions for ablating tumors.



FIGS. 3A-3D schematically illustrate a series of symmetric ablation zones 500a created by a RF energy delivery probe 410a. The symmetric ablation zones are symmetric about the poles of the first conductor 420 and the second conductor 450. The symmetric ablation zones 500a are three-dimensional, even though the FIGS. 3A-3D illustrate them as two-dimensional. As compared with the RF energy delivery probe 410 of FIGS. 1-2B, FIGS. 3A-3D illustrate variation on the design of the geometry of the distal tip of the RF energy delivery probe 410, thus the reference numerals in these figures are designated with a final letter “a” to indicate the variation with the prior embodiment. Nonetheless, disclosure related in connection with the embodiment of FIGS. 1-2B may be applied to the embodiment of FIGS. 3A-3D and vice versa. In the embodiment of FIGS. 3A-3D, a distal thermocouple 454a and proximal thermocouples 424a, 425a, 426a, 427a are shown in each of FIGS. 3A-3D.



FIG. 3A illustrates a first ablation zone 500a with a length L1. In some embodiments, the length of L1 is 1 cm. FIG. 3B illustrates a second configuration where the ablation zone 500a has a length L2. In some embodiments, the length of L2 is 2 cm. FIG. 3C illustrates a third configuration where the ablation zone 500a has a length L3. In some embodiments, the length of L3 is 3 cm. FIG. 3D illustrates a fourth configuration where the ablation zone 500a has a length L4. In some embodiments, the length of L4 is 4 cm. In other embodiments, the length of L4 is 3.5 cm. While the present disclosure contemplates multiple ablation zone sizes, the present disclosure is not limited to these proposed ablation zone sizes. In fact, multiple ablation zone sizes are within the scope of these disclosure based on a single probe design.


The size of the ablation zone 500a may be controlled by modulating the delivery of electrical energy, such as radiofrequency energy, to the RF energy delivery probe 410a. In the illustrated embodiment, correlation between a 5 mm offset proximal thermocouples, 424a, 425a, 426a, and 427a, and 1 cm increments of the ablation zone size (due to 5 mm growth of the ablation zone 500a on each side of the distal tip of the RF energy delivery probe 410a) is shown. Again, in other embodiments, different sizes of ablation zone, including different increments for controlling the ablation zone 500a size, and different placement of the proximal thermocouples 424a, 425a, 426a, and 427a may be used.


The medical device may be configured to create symmetric ablation zones even when the RF energy delivery probe 410a is articulated along a distal portion (such as distal portion 412 of FIG. 1) because of the rigid and straight portion 414 where the thermocouples 424, 425, 426, and 427 are disposed.



FIGS. 4A-4C illustrate a method for treating a spinal tumor or lesion 610 in one or more vertebral bodies 600 of a patient using the medical device 400 of FIG. 1 by unipedicular access. For example, some embodiments of a medical procedure may comprise obtaining the medical device (400 of FIG. 1) and inserting the distal end 401 of the RF energy delivery probe 410 into a vertebral body of a patient (e.g., a sedated patient in the prone position). In some embodiments, the distal end 401 of the RF energy delivery probe 410 may be pointed and the pointed distal end 401 may facilitate penetration of bone within the vertebra of the patient. Further, in some embodiments, the RF energy delivery probe 410 has sufficient strength to prevent buckling of the RF energy delivery probe 410 as the distal end of the RF energy delivery probe 410 is inserted within a vertebra (e.g., across the cortical bone) of the patient. In some embodiments, the distal end 401 of the RF energy delivery probe 410 is inserted into the patient via an introducer (not shown). In other embodiments, the distal end 401 of the RF energy delivery probe 410 may be inserted into the soft tissue of the patient without using an introducer.



FIG. 4A illustrates the RF energy delivery probe 410 inserted into the vertebra 600 of a patient with the tumor 610. The distal portion (412 of FIG. 1) of the RF energy delivery probe 410 may be articulated to place the RF energy delivery probe 410 in a predetermined position. The RF energy delivery probe 410 may be activated and the RF generator may provide energy for the RF energy delivery probe 410 to ablate the tumor 610. The RF energy delivery probe 410 may then create a symmetric ablation zone 500 (similar to the ablation zones 500a discussed in connection with FIGS. 3A-3D). With reference to FIG. 1 and FIGS. 2A-2B, the distal thermocouple 454 and the proximal thermocouples 424, 425, 426, 427 may detect the temperature of the surrounding tissue and provide the temperature feedback to the base unit 200, which may be displayed on the display 250. This information may then be fed into the generator algorithm to maintain a symmetric ablation zone to ablate the tumor 610 and avoid damaging surrounding tissue.



FIG. 4B illustrates ablated tissue 620 of the tumor 610 as the tissue reaches a predetermined temperature such as 50 degrees Celsius, or thermal dose. Once the tumor 610 reaches the predetermined temperature, the RF generator may turn off the power, or otherwise modify current delivery to the RF energy delivery probe 410. The diameter of the ablation zone 500 may be determined based on the size of the tumor 610. If the tumor 610 is smaller, the ablation zone 500 may be smaller and a subset of the proximal thermocouples 424, 425, 426, 427 may be used to detect the temperature in and immediately adjacent the ablation zone 500. If the ablation zone 500 is larger, all of the proximal thermocouples 424, 425, 426, 427 may be used to detect the temperature within and adjacent the ablation zone 500. That is to say, while all the proximal thermocouples 424, 425, 426, and 427 may monitor temperature and provide feedback to the base unit 200, in some procedures, only a subset of the proximal thermocouples 424, 425, 426, and 427 may be within and/or immediately adjacent the ablation zone 500. FIG. 4C illustrates the dead tissue 620 of the ablated tumor 610 with the RF energy delivery probe 410 removed from the vertebra 600 of the patient.


As discussed previously, FIG. 5 illustrates a tumor ablation system 100′ with two medical devices 400 and 400″ for performing a bipedicular vertebral access to treat tumors. In the illustrated embodiment, the tumor ablation system 100′ comprises the base unit 200, remote 300, and medical device 400 of the tumor ablation system 100 of FIG. 1. That is to say, a tumor ablation system may be configured with a single medical device 400 or two medical devices 400 and 400″, depending on the desired treatment. For clarity with connecting the disclosure of the tumor ablation system 100 and the tumor ablation system 100′, the tumor ablation system 100′ is shown as comprising the noted elements of the tumor ablation system 100. Embodiments wherein elements such as the base unit 200 and remote 300 are configured for use with only one, with one or two, with only two, or with other numbers of medical devices 400, 400″ are likewise within the scope of this disclosure.


The second medical device, medical device 400″, may be similar to the first medical device, medical device 400, or may be different based on treatment needs of the patient. The remote 300 may allow the user to adjust the energy provided to each medical device 400 and 400″. In some embodiments, energy adjustment may be done automatically via an algorithm. For example, the remote 300 may have a button 320 for controlling the amount of energy to the medical device 400, 400″ plugged into port 220 and a button 340 for controlling the amount of energy to the medical device 400, 400″ plugged into port 240.


As discussed above, each medical device 400 and 400″ may include a plurality of identifying features to help identify which medical device 400 and 400″ is coupled to which port 220 and 240.



FIGS. 6A-6C illustrate a method for treating a spinal tumor 610′ in one or more vertebral bodies 600′ of a patient using the medical devices 400 and 400″ using bipedicular access. For example, some embodiments of a medical procedure may involve obtaining the medical devices 400 and 400″ and inserting the distal ends 401 and 401″ of the RF energy delivery probes 410, 410″ into a vertebral body of a patient (e.g., a sedated patient in the prone position). In other embodiments, the distal end 412 and 412″ of the first tubular conductor 420 may be inserted into a vertebral body of the patient. In some embodiments, the distal ends 401 and 401″ of the RF energy delivery probes 410, 410″ or the distal end 412 and 412″ of the first tubular conductor 420 may be pointed and the pointed distal ends may facilitate penetration of bone within the vertebra 600′ of the patient. In some embodiments, the RF energy delivery probes 410, 410″ have sufficient strength to prevent buckling of the RF energy delivery probes 410, 410″ as the distal ends 401 and 401″ of the RF energy delivery probes 410, 410″ are inserted within the vertebra 600′ (e.g., across the cortical bone) of the patient. In some embodiments, the distal ends 401 and 401″ of the RF energy delivery probes 410, 410″ are inserted into the patient via an introducer (not shown). In other embodiments, the distal ends 401 and 401″ of the RF energy delivery probes 410, 410″ may be inserted into the soft tissue of the patient without using an introducer.



FIG. 6A illustrates the medical devices 400 and 400″ inserted into a vertebra 600′ of a patient with a tumor 610′. The distal portions 412 and 412″ of the RF energy delivery probes 410 and 410″ may be articulated to place the RF energy delivery probes 410 and 410″ in predetermined positions. The RF energy delivery probes 410 and 410″ may be activated and the RF generator may provide energy to the RF energy delivery probes 410 and 410″ to ablate the tumor 610′. The RF energy delivery probes 410 and 410″ may each create symmetric ablation zones 500, 500′, similar to the ablation zones 500 discussed in FIGS. 3A-3D. The distal thermocouples 454 and 454″ and the proximal thermocouples 424, 425, 426, 427, 424″, 425″, 426″, and 427″ may detect the temperature of the surrounding tissue and provide the temperature feedback to the base unit 200, which may be displayed on the display 250. This information may be fed into the generator algorithm to maintain a symmetric ablation zone 500, 500′ to ablate the tumor 610′ and avoid damaging surrounding tissue.



FIG. 6B illustrates the ablated tissue 620′ of the tumor 610′ as the tissue reaches a predetermined thermal dose or temperature, such as 60 degrees Celsius. Once the tumor 610′ reaches the predetermined temperature or thermal dose, the RF generator may turn off the power, or otherwise modify current delivery to the RF energy delivery probes 410 and 410″. The diameter of the ablation zones 500, 500′ may be determined based on the size of the tumor 610′. If the tumor 610′ is smaller, the ablation zones 500, 500′ may be smaller and only a subset of the proximal thermocouples 424, 425, 426, 427, 424″, 425″, 426″, and 427″ may be used to detect the temperature in and immediately adjacent the ablation zones 500, 500′, as also described above in connection with FIG. 4B. FIG. 6C illustrates the dead tissue 620′ of the ablated tumor 610′ with the RF energy delivery probes 410 and 410′ removed from the vertebra 600′ of the patient.



FIG. 7 schematically illustrates a flexible thermocouple circuit 480 for the thermocouples 454, 424, 425, 426, and 427. (This disclosure may also be applied analogously to the thermocouples 454″, 424″, 425″, 426″, and 427″ of the medical device 400″.) The flexible thermocouple circuit 480 may be configured to provide flexibility and repeatability, enabling the flexible thermocouple circuit 480 to bend and articulate with the RF energy delivery probe 410. The flexible thermocouple circuit 480 may include a plurality of tails. In the illustrated embodiment, the flexible thermocouple circuit 480 has a first tail 428 and a second tail 455. The first tail 428 houses the thermocouples 424, 425, 426, and 427 at its distal end, with the thermocouples 424, 425, 426, and 427 spaced apart at a distal portion 429. As discussed previously, the thermocouples 424, 425, 426, and 427 may be evenly spaced apart or may be unevenly spaced apart. The first tail 428 may be disposed between the first tubular insulator 430 and the second tubular insulator 440.


The second tail 455 houses the distal thermocouple 454 at a distal portion 482. The second tail 455 is also illustrated in FIG. 2B, and the second tail 455 may extend along the inner diameter of the second tubular conductor 450 to the distal portion 452 of the second tubular conductor 450. In some embodiments, the first tail 428 may be thicker than the second tail 455.



FIG. 8 illustrates a flowchart for the different circuits of the tumor ablation system 100. The flexible thermocouple circuit 480 is configured to couple to a daughter board 490 that is disposed within the housing 460 of the medical device 400. The daughter board 490 is disposed within the housing 460 and is able to communicate with the base unit 200 via the cable and plug 470. Accordingly, the temperatures measured by the thermocouples 424, 425, 426, 427, 454 may be communicated to the base unit 200 and the RF generator algorithm. The flexible thermocouple circuit 480 may include a ZIF connector 484 for connecting the flexible thermocouple circuit 480 to a daughter board 490.


The daughter board 490 may further include a local cold junction compensation system. The temperature at the local cold junction is known, thereby making it possible to determine the temperatures at the thermocouples 424, 425, 426, 427, and 454. The local cold junction compensation system may comprise a thermistor or an integrated circuit.


The medical device 400 may further include an RF circuit 492 for delivery of the RF energy from the RF generator to the RF energy delivery probe 410.


The RF energy delivery probes discussed in the instant disclosure, such as RF energy delivery probe 410, may be used in various ablation procedures for treating tumors within a patient. The RF energy deliver probe 410 may be inserted within a patient to a tumor location. The tumor may be located in a variety of different areas within the patient. The RF energy delivery probe 410 may be guided to the tumor location via imaging, such as fluoroscopy, to ensure that the RF energy delivery probe 410 is delivered to the proper location. In some embodiments, the display 250 of the base unit 200 may display an overlay of the imaging and the position of the RF energy delivery probe 410.


The first conductor and the second conductor may be disposed within the tumor. RF energy may be delivered from the generator and produce a current between the first conductor and the second conductor. The first pole may be RF+ pole and the second pole may be a return pole, or RF− pole. As the electrical current passes between the first pole and the second pole, the current may pass through tissue of the patient (e.g., the ablation zone), thereby ablating by heating (and potentially killing) the adjacent tissue (e.g., tumor cells). The ablation zone created by the RF energy delivery probe 410 may be symmetric.


As discussed previously, the RF energy delivery probe 410 may comprise one or more thermocouples, 454, 424, 425, 426, and 427. Based on the temperature information obtained from the one or more thermocouples, 454, 424, 425, 426, and 427, the duration, position, and/or magnitude of the delivered thermal energy may be tailored to ablate tumor tissue within a desired region of the tumor while avoiding the delivery of damaging amounts of thermal energy to healthy tissue. The temperature information may be fed to the generator algorithm to determine the amount of power to provide to the first pole and the second pole


The RF energy delivery probe 410 may be inserted into a vertebral body of the patient. If a single RF energy delivery probe 410 is used to access the vertebral body, this is called unipedicular access. A second RF energy delivery probe 410′ may be used to access the vertebral body, this is called bipedicular access.


In some embodiments, the distal portion 412 of the RF energy delivery probe 410 may be articulated relative to the proximal portion of the RF energy delivery probe. In other words, the RF energy delivery probe 410 transitions from a linear configuration to a non-linear configuration.



FIGS. 9A-9C illustrate the RF energy delivery probe 410 in three different configurations. FIG. 9A illustrates the RF energy delivery probe 410 in a straight configuration. FIG. 9B illustrates the RF energy delivery probe 410 in an articulated configuration. FIG. 9C illustrates the RF energy delivery probe 410 in an hyperextended configuration. During an ablation procedure, the if the RF energy delivery probe 410 is articulated to reach the tumor (as illustrated in FIG. 9B), it may be desirable to return the RF energy delivery probe 410 to a straight configuration (as illustrated in FIG. 9A) in order to remove the RF energy delivery probe 410 through a sheath and out of the body. In some circumstances, when the RF energy delivery probe is articulated, the RF energy delivery probe 410 develops a positional memory that causes the RF energy delivery probe to not be entirely straight when returned to a straight configuration. This slight variation (due to memory effects of the materials of the device) at the distal portion 412 that is not straight can make it more difficult to remove the RF energy delivery probe 410. Accordingly, the RF energy delivery probe 410 may be configured such that the distal portion 412 thereof may be articulated back “past” the initial zero position to compensate for any memory effects in the materials. Thus, a user may hyperextend the RF energy delivery probe 410 slightly past the straight configuration (as illustrated in FIG. 9C) up to an angle 81, causing the RF energy delivery probe 410 to hyperextend past the longitudinal axis of the RF energy delivery probe 410. In some embodiments, the angle θ1 may extend up to 20° past the longitudinal axis of the RF energy delivery probe 410. In some embodiments, the angle θ1 may extend up to 10° past the longitudinal axis of the RF energy delivery probe 410. This hyperextension may counteract the positional memory of the articulation and facilitates the removal of the RF energy delivery probe 410. Angle θ1 is measured in the opposite direction as the angle at which the RF energy delivery probe 410 is configured for primary articulation. In other words, primary articulation (such as shown in FIG. 9B) would be measured in a first direction from a neutral axis of the RF energy delivery probe 410 while the ability to “hyperextend” refers to the ability of the RF energy delivery probe 410 to return back toward, and past, the neutral axis when returning from the primary articulated state.


Any methods disclosed herein include one or more steps or actions for performing the described method. The method steps and/or actions may be interchanged with one another. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order and/or use of specific steps and/or actions may be modified. Moreover, sub-routines or only a portion of a method described herein may be a separate method within the scope of this disclosure. Stated otherwise, some methods may include only a portion of the steps described in a more detailed method.


Reference throughout this specification to “an embodiment” or “the embodiment” means that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment. Thus, the quoted phrases, or variations thereof, as recited throughout this specification are not necessarily all referring to the same embodiment.


Similarly, it should be appreciated by one of skill in the art with the benefit of this disclosure that in the above description of embodiments, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. This method of disclosure, however, is not to be interpreted as reflecting an intention that any claim requires more features than those expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following this Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment. This disclosure includes all permutations of the independent claims with their dependent claims.


Recitation in the claims of the term “first” with respect to a feature or element does not necessarily imply the existence of a second or additional such feature or element. It will be apparent to those having skill in the art that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the present disclosure.

Claims
  • 1. A system for tumor ablation, the system comprising: a first probe comprising: a first conductor;a second conductor disposed distal to the first conductor;an insulator bushing disposed between the first conductor and the second conductor;a distal thermocouple to measure a temperature at a location on the second conductor;a plurality of thermocouples that are disposed between the first conductor and the second conductor; anda generator to produce a current to be conducted between the first conductor and the second conductor to create an ablation region;wherein the system is configured to create a symmetric ablation region.
  • 2. The system for tumor ablation of claim 1, wherein the plurality of thermocouples are disposed proximal to the insulator bushing.
  • 3. The system for tumor ablation of claim 1, wherein the plurality of thermocouples are evenly spaced.
  • 4. The system for tumor ablation of claim 1, wherein the first probe further comprises a first insulator and a second insulator disposed radially between the first conductor and the second conductor, and wherein the plurality of thermocouples are disposed radially and longitudinally between the first insulator and the second insulator.
  • 5. The system for tumor ablation of claim 1, wherein the plurality of thermocouples and the distal thermocouple are disposed on a flexible thermocouple circuit.
  • 6. The system for tumor ablation of claim 5, wherein the flexible thermocouple circuit comprises at least two tails, wherein the plurality of thermocouples are disposed on a first tail and the distal thermocouple is disposed on a second tail, and wherein the second tail extends along the center of an inner diameter of the second conductor to a distal portion of the second conductor.
  • 7. The system for tumor ablation of claim 1, wherein a distal portion of the first probe is configured to articulate relative to a proximal portion of the first probe.
  • 8. The system for tumor ablation of claim 1, wherein the system further comprises a remote that manually controls the energy delivered to the first probe.
  • 9. The system for tumor ablation of claim 1, wherein the system is configured to create a 1 cm symmetric ablation region.
  • 10. The system for tumor ablation of claim 1, wherein the system is configured to create a 3.5 cm symmetric ablation region.
  • 11. The system for tumor ablation of claim 1, wherein the generator further comprises a first port and a second port, wherein the first probe is configured to couple to the first port and a second probe is configured to couple to the second port.
  • 12. The system for tumor ablation of claim 11, wherein the first port comprises a first indicia and the second port comprises a second indicia, wherein the first probe comprises a third indicia and the second probe comprises a fourth indicia, andwherein the first indicia corresponds with the indicia of the probe that is coupled to the first port and the second indicia corresponds with the indicia of the probe that is coupled to the second port.
  • 13. An RF energy delivery probe for tumor ablation comprising: a first tubular conductor;a second tubular conductor partially disposed within the first tubular conductor and disposed such that a distal portion of the second conductor is distal to the first conductor;an insulator bushing disposed between the first conductor and the second conductor; anda distal thermocouple disposed at a distal end of the second tubular conductor to measure a temperature at the distal end of the probe;a plurality of thermocouples disposed between the first tubular conductor and the second tubular conductor and proximal to the distal thermocouple,wherein the RF energy delivery probe is configured to create an ablation region.
  • 14. The RF energy delivery probe of claim 13, further comprising a first insulator and a second insulator disposed radially between the first conductor and the second conductor, and wherein the plurality of thermocouples are disposed between the first insulator and the second insulator.
  • 15. The RF energy delivery probe of claim 13, wherein a distal portion of the RF energy delivery probe is configured to articulate relative to a proximal portion of the probe.
  • 16. The RF energy delivery probe of claim 13, wherein the distal portion of the second tubular conductor is configured to extend and retract in the longitudinal direction of the RF energy delivery probe relative to the first tubular conductor.
  • 17. The RF energy delivery probe of claim 13, wherein the plurality of thermocouples and the distal thermocouple are disposed on a flexible thermocouple circuit.
  • 18. The system for tumor ablation of claim 17, wherein the flexible thermocouple circuit comprises at least two tails, wherein the plurality of thermocouples are disposed on a first tail and the distal thermocouple is disposed on a second tail, and wherein the second tail extends along the center of an inner diameter of the second tubular conductor to a distal portion of the second tubular conductor.
  • 19. A method of ablating tumors in a patient, comprising: inserting a first RF energy delivery probe within a patient to a tumor location, wherein the RF energy delivery probe comprises: a first conductor,a second conductor disposed distal to the first conductor; andan insulator bushing disposed between the first conductor and the second conductor; anda plurality of thermocouples that are disposed between the first conductor and the second conductor;producing a current between the first conductor and the second conductor to create a symmetric ablation zone; andmeasuring a temperature at a point on the second conductor.
RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 62/757,596, filed on Nov. 8, 2018 and titled “Tumor Ablation Device and Related Systems and Methods,” and U.S. Provisional Application No. 62/757,578, filed on Nov. 8, 2018 and titled “Ablation Systems with Parameter-Based Modulation and Related Devices and Methods,” both of which are incorporated herein by reference in their entireties.

US Referenced Citations (650)
Number Name Date Kind
2688329 Wallace Sep 1954 A
3140623 Hoose Jul 1964 A
3228400 Armao Jan 1966 A
3503385 Stevens Mar 1970 A
3625200 Muller Dec 1971 A
3664344 Bryne May 1972 A
3794039 Kollner et al. Feb 1974 A
3908637 Doroshow Sep 1975 A
4033331 Guss et al. Jul 1977 A
4131597 Bluethgen et al. Dec 1978 A
4236520 Anderson Dec 1980 A
4276880 Malmin Jul 1981 A
4294251 Grennwald et al. Oct 1981 A
4337773 Raftopoulos et al. Jul 1982 A
4386717 Koob Jun 1983 A
4399814 Pratt, Jr. et al. Aug 1983 A
4411266 Cosman Oct 1983 A
4456017 Miles Jun 1984 A
4473077 Noiles Sep 1984 A
4476861 Dimakos et al. Oct 1984 A
4578061 Lemelson Mar 1986 A
4586923 Gould et al. May 1986 A
4595006 Burke et al. Jun 1986 A
4619263 Frisbie et al. Oct 1986 A
4627434 Murray Dec 1986 A
4641654 Samson et al. Feb 1987 A
4653489 Tronzo Mar 1987 A
4668295 Bajpai May 1987 A
4682596 Bales Jul 1987 A
4719968 Speros Jan 1988 A
4722948 Sanderson Feb 1988 A
4731054 Billeter et al. Mar 1988 A
4742817 Kawashima et al. May 1988 A
4747840 Ladika et al. May 1988 A
4748969 Wardle Jun 1988 A
4784638 Ghajar et al. Nov 1988 A
4795602 Pretchel et al. Jan 1989 A
4842603 Draenert Jun 1989 A
4843112 Gerhart et al. Jun 1989 A
4846814 Ruiz Jul 1989 A
4865586 Hedberg Sep 1989 A
4869906 Dingeldein et al. Sep 1989 A
4888366 Chu et al. Dec 1989 A
4900303 Lemelson Feb 1990 A
4961730 Bodicky et al. Oct 1990 A
4961731 Poncy Oct 1990 A
4963151 Ducheyene et al. Oct 1990 A
4969870 Kramer et al. Nov 1990 A
4969888 Scholten et al. Nov 1990 A
4982730 Royce Jan 1991 A
4998923 Samson et al. Mar 1991 A
5004501 Faccioli Apr 1991 A
5017627 Bonfield May 1991 A
5046513 O'Leary et al. Sep 1991 A
5049137 Thompson Sep 1991 A
5049157 Mittelmeier et al. Sep 1991 A
5059193 Kuslich Oct 1991 A
5085659 Rydell Feb 1992 A
5085861 Gerhart et al. Feb 1992 A
5088991 Weldon Feb 1992 A
5116305 Milder et al. Feb 1992 A
5092891 Kummer et al. Mar 1992 A
5103804 Abele Apr 1992 A
5108404 Scholten et al. Apr 1992 A
5112303 Pudenz et al. May 1992 A
5114414 Buchbinder May 1992 A
5147334 Moss Sep 1992 A
5156606 Chin Oct 1992 A
5163431 Greip Nov 1992 A
5184757 Giannuzzi Feb 1993 A
5188619 Myers Feb 1993 A
5196201 Larsson et al. Mar 1993 A
5197971 Bonutti Mar 1993 A
5211631 Sheaff May 1993 A
5231989 Middleman et al. Aug 1993 A
5242082 Giannuzzi Sep 1993 A
5264214 Rhee et al. Nov 1993 A
5266248 Ohtsuka et al. Nov 1993 A
5269750 Grulke et al. Dec 1993 A
5282821 Donahue Feb 1994 A
5284128 Hart Feb 1994 A
5285795 Ryan et al. Feb 1994 A
5295980 Ersek Mar 1994 A
5296026 Monroe et al. Mar 1994 A
5308342 Sepetka et al. May 1994 A
5322064 Lundquist Jun 1994 A
5322505 Krause et al. Jun 1994 A
5334181 Rubinsky et al. Aug 1994 A
5336699 Cooke et al. Aug 1994 A
5342356 Ellman Aug 1994 A
5343877 Park Sep 1994 A
5352715 Wallace et al. Oct 1994 A
5356629 Sander Oct 1994 A
5360416 Ausherman et al. Nov 1994 A
5368598 Hasson Nov 1994 A
5372587 Hammerslag et al. Dec 1994 A
5378234 Hammerslag et al. Jan 1995 A
5380307 Chee et al. Jan 1995 A
5385563 Gross Jan 1995 A
5389073 Imran Feb 1995 A
5425770 Piez et al. Jun 1995 A
5431168 Webster, Jr. Jul 1995 A
5431639 Shaw Jul 1995 A
5437636 Snoke et al. Aug 1995 A
5449301 Hanna et al. Sep 1995 A
5449351 Zohmann Sep 1995 A
5458597 Edwards et al. Oct 1995 A
5480382 Hammerslag et al. Jan 1996 A
5484424 Cottenceau et al. Jan 1996 A
5489275 Thompson et al. Feb 1996 A
5496330 Bates et al. Mar 1996 A
5512610 Lin Apr 1996 A
5514130 Baker May 1996 A
5514137 Coutts May 1996 A
5531715 Engelson et al. Jul 1996 A
5535922 Maziarz Jul 1996 A
5549542 Kovalcheck Aug 1996 A
5549637 Crainich Aug 1996 A
5549679 Kuslich Aug 1996 A
5554114 Wallace et al. Sep 1996 A
5571085 Accisano, III Nov 1996 A
5571088 Lennox Nov 1996 A
5574075 Draemert Nov 1996 A
5599346 Edwards et al. Feb 1997 A
5616121 McKay Apr 1997 A
5620447 Smith et al. Apr 1997 A
5620467 Wagner Apr 1997 A
5624396 McNamara et al. Apr 1997 A
5628771 Mizukawa et al. May 1997 A
5637090 McGee Jun 1997 A
5637091 Hakky et al. Jun 1997 A
5662680 Desai Sep 1997 A
5681282 Eggers et al. Oct 1997 A
5681289 Wilcox et al. Oct 1997 A
5681317 Caldarise Oct 1997 A
5685826 Bonutti Nov 1997 A
5695513 Johnson et al. Dec 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5700157 Chung Dec 1997 A
5704926 Sutton Jan 1998 A
5709697 Ratcliff et al. Jan 1998 A
5725568 Hastings Mar 1998 A
5735829 Cherian Apr 1998 A
5741320 Thornton et al. Apr 1998 A
5766153 Eggers et al. Jun 1998 A
5800408 Strauss et al. Sep 1998 A
5810804 Gough Sep 1998 A
5810867 Zarbateny et al. Sep 1998 A
5820592 Hammerslag et al. Oct 1998 A
5833632 Jacobsen et al. Nov 1998 A
5833692 Cesarini et al. Nov 1998 A
5847046 Jiang et al. Dec 1998 A
5849028 Chen Dec 1998 A
5851212 Zirps et al. Dec 1998 A
5855577 Murphy-Chutorian et al. Jan 1999 A
5858003 Atala Jan 1999 A
5860952 Quinn Jan 1999 A
5860974 Abele Jan 1999 A
5876373 Giba et al. Mar 1999 A
5891027 Tu Apr 1999 A
5902251 Vanhooydonk May 1999 A
5902839 Lautenschlager et al. May 1999 A
5914356 Erbe Jun 1999 A
5921956 Grinberg et al. Jul 1999 A
5928239 Mirza Jul 1999 A
5931829 Burbank et al. Aug 1999 A
5944715 Goble et al. Aug 1999 A
5947964 Eggers Sep 1999 A
5972015 Scribner et al. Oct 1999 A
5997581 Khalili Dec 1999 A
6019765 Thornhill et al. Feb 2000 A
6027487 Crocker Feb 2000 A
6030360 Biggs Feb 2000 A
6048346 Reiley et al. Apr 2000 A
6059739 Baumann May 2000 A
6063078 Wittkampf May 2000 A
6064902 Haissaguerre May 2000 A
6066154 Reiley et al. May 2000 A
6066176 Oshida May 2000 A
6073051 Sharkey et al. Jun 2000 A
6080801 Draenert et al. Jun 2000 A
6099514 Sharkey et al. Aug 2000 A
6106524 Eggers Aug 2000 A
6106539 Fortier Aug 2000 A
6110155 Baudino Aug 2000 A
6123702 Swanson Sep 2000 A
6127597 Beyar et al. Oct 2000 A
6135999 Fanton et al. Oct 2000 A
6146355 Biggs Nov 2000 A
6156254 Andrews et al. Dec 2000 A
6183435 Bumbalough et al. Feb 2001 B1
6203507 Wadsworth et al. Mar 2001 B1
6203574 Kawamura Mar 2001 B1
6228052 Pohndorf May 2001 B1
6228904 Yadav et al. May 2001 B1
6231569 Bek et al. May 2001 B1
6231615 Preissman May 2001 B1
6235043 Reiley et al. May 2001 B1
6241734 Scribner et al. Jun 2001 B1
6248110 Reiley et al. Jun 2001 B1
6251092 Qin et al. Jun 2001 B1
6258086 Ashley et al. Jul 2001 B1
6270476 Santoianni et al. Aug 2001 B1
6280413 Clark et al. Aug 2001 B1
6280434 Kinoshita et al. Aug 2001 B1
6280441 Ryan Aug 2001 B1
6280456 Scribner et al. Aug 2001 B1
6280473 Lemperle et al. Aug 2001 B1
6283960 Ashley Sep 2001 B1
6291547 Lyles Sep 2001 B1
6312428 Eggers Nov 2001 B1
6312454 Stockel et al. Nov 2001 B1
6332894 Stalcup et al. Dec 2001 B1
6348055 Preissman Feb 2002 B1
6352533 Ellman et al. Mar 2002 B1
6358251 Mirza Mar 2002 B1
6375659 Erbe et al. Apr 2002 B1
6383188 Kuslich et al. May 2002 B2
6383190 Preissman May 2002 B1
6395007 Bhatnagar et al. May 2002 B1
6408889 Komachi Jun 2002 B1
6409722 Hoey et al. Jun 2002 B1
6428894 Babich et al. Aug 2002 B1
6437019 Rusin et al. Aug 2002 B1
6440138 Reiley et al. Aug 2002 B1
6447506 Swanson et al. Sep 2002 B1
6447514 Stalcup et al. Sep 2002 B1
6464683 Samuelson et al. Oct 2002 B1
6478793 Cosman et al. Nov 2002 B1
6479565 Stanley Nov 2002 B1
6484904 Horner et al. Nov 2002 B1
6506217 Arnett Jan 2003 B1
6511471 Rosenman et al. Jan 2003 B2
6524296 Beals Feb 2003 B1
6565588 Clement et al. May 2003 B1
6575969 Rittman et al. Jun 2003 B1
6575978 Peterson et al. Jun 2003 B2
6576249 Gendler et al. Jun 2003 B1
6582446 Marchosky Jun 2003 B1
6592559 Pakter et al. Jul 2003 B1
6599961 Pienkowski et al. Jul 2003 B1
6602248 Sharps et al. Aug 2003 B1
6607544 Boucher et al. Aug 2003 B1
6613054 Scribner et al. Sep 2003 B2
6620162 Kuslich et al. Sep 2003 B2
6622731 Daniel et al. Sep 2003 B2
6623448 Slater Sep 2003 B2
6638268 Naizi Oct 2003 B2
6663647 Reiley et al. Oct 2003 B2
6641587 Scribner et al. Nov 2003 B2
6645213 Sand et al. Nov 2003 B2
6676665 Foley et al. Jan 2004 B2
6679886 Weikel et al. Jan 2004 B2
6689823 Bellare et al. Feb 2004 B1
6692532 Healy et al. Feb 2004 B1
6716216 Boucher et al. Apr 2004 B1
6719761 Reiley et al. Apr 2004 B1
6719773 Boucher et al. Apr 2004 B1
6726691 Osorio et al. Apr 2004 B2
6730095 Olson, Jr. et al. May 2004 B2
6740090 Cragg et al. May 2004 B1
6740093 Hochschuler et al. May 2004 B2
6743239 Kuehn et al. Jun 2004 B1
6746451 Middleton et al. Jun 2004 B2
6752863 Lyles et al. Jun 2004 B2
6753007 Haggard et al. Jun 2004 B2
6770079 Bhatnagar et al. Aug 2004 B2
6814734 Chappuis et al. Nov 2004 B2
6814736 Reiley et al. Nov 2004 B2
6818001 Wulfman et al. Nov 2004 B2
6832984 Stelzer et al. Dec 2004 B2
6835193 Epstein et al. Dec 2004 B2
6837867 Kortelling Jan 2005 B2
6863672 Reiley et al. Mar 2005 B2
6869430 Balbierz et al. Mar 2005 B2
6869445 Johnson Mar 2005 B1
6875219 Arramon Apr 2005 B2
6881214 Cosman Apr 2005 B2
6887246 Bhatnagar et al. May 2005 B2
6899715 Beaty May 2005 B1
6899719 Reiley et al. May 2005 B2
6907884 Pellegrino et al. Jun 2005 B2
6913594 Coleman et al. Jul 2005 B2
6916306 Jenkins et al. Jul 2005 B1
6923813 Phillips Aug 2005 B2
6945956 Waldhauser et al. Sep 2005 B2
6953594 Lee et al. Oct 2005 B2
6955716 Xu et al. Oct 2005 B2
6976987 Flores Dec 2005 B2
6979312 Shimada Dec 2005 B2
6979352 Reynolds Dec 2005 B2
6981981 Reiley et al. Jan 2006 B2
6991616 Bencini et al. Jan 2006 B2
6998128 Haggard et al. Feb 2006 B2
7004930 Marshall Feb 2006 B2
7004945 Boyd et al. Mar 2006 B2
7008433 Voellmicke et al. Mar 2006 B2
7018460 Xu et al. Mar 2006 B2
7022133 Yee et al. Apr 2006 B2
7029468 Honebrink Apr 2006 B2
7044954 Reiley et al. May 2006 B2
7059330 Makower et al. Jun 2006 B1
7063682 Whayne et al. Jun 2006 B1
7066942 Treace Jun 2006 B2
RE39196 Ying et al. Jul 2006 E
7077842 Cosman Jul 2006 B1
7081122 Reiley et al. Jul 2006 B1
7081161 Genge et al. Jul 2006 B2
7091258 Neubert et al. Aug 2006 B2
7091260 Kūhn Aug 2006 B2
7094202 Nobis et al. Aug 2006 B2
7094286 Liu Aug 2006 B2
7108696 Daniel et al. Sep 2006 B2
7109254 Müller et al. Sep 2006 B2
7112205 Carrison Sep 2006 B2
7114501 Johnson et al. Oct 2006 B2
7138442 Smith et al. Nov 2006 B2
7153306 Ralph et al. Dec 2006 B2
7153307 Scribner et al. Dec 2006 B2
7156843 Skarda Jan 2007 B2
7156845 Mulier Jan 2007 B2
7160296 Pearson et al. Jan 2007 B2
7166121 Reiley et al. Jan 2007 B2
7172629 McKay et al. Feb 2007 B2
7179255 Lettice et al. Feb 2007 B2
7186234 Dahla et al. Mar 2007 B2
7186761 Soffiati et al. Mar 2007 B2
7226481 Kuslich et al. Jun 2007 B2
7252671 Scribner et al. Aug 2007 B2
7267683 Sharkey et al. Sep 2007 B2
7270661 Dahla et al. Sep 2007 B2
7294127 Leung Nov 2007 B2
7465318 Sennett et al. Dec 2008 B2
7480533 Cosman et al. Jan 2009 B2
7503920 Siegal Mar 2009 B2
7544196 Bagga et al. Jun 2009 B2
7559932 Truckai et al. Jul 2009 B2
7569054 Michelson Aug 2009 B2
7572263 Preissman Aug 2009 B2
7591822 Olson, Jr. et al. Sep 2009 B2
7625364 Corcoran et al. Dec 2009 B2
7641664 Pagano Jan 2010 B2
7731720 Sand et al. Jun 2010 B2
7811291 Liu et al. Oct 2010 B2
7824403 Vaska Nov 2010 B2
7842041 Liu et al. Nov 2010 B2
7887543 Sand et al. Feb 2011 B2
7905884 Simonton et al. Mar 2011 B2
7918874 Siegal Apr 2011 B2
7972340 Sand et al. Jul 2011 B2
7976542 Cosman Jul 2011 B1
8034071 Scribner et al. Oct 2011 B2
8246627 Vanleeuwen et al. Aug 2012 B2
8518036 Leung et al. Aug 2013 B2
8583260 Knudson Nov 2013 B2
8591507 Kramer et al. Nov 2013 B2
8663226 Germain Mar 2014 B2
RE44883 Cha May 2014 E
8758349 Germain et al. Jun 2014 B2
8827981 Liu et al. Sep 2014 B2
8864760 Kramer et al. Oct 2014 B2
8936631 Nguyen Jan 2015 B2
9113974 Germain Aug 2015 B2
9125671 Germain et al. Sep 2015 B2
9161809 Germain et al. Oct 2015 B2
9421057 Germain Aug 2016 B2
9743938 Germain et al. Aug 2017 B2
20010011174 Reiley et al. Aug 2001 A1
20010023349 Van Tassel et al. Sep 2001 A1
20020007180 Wittenberger et al. Jan 2002 A1
20020013600 Scribner et al. Jan 2002 A1
20020016583 Cragg Feb 2002 A1
20020026195 Layne et al. Feb 2002 A1
20020026197 Foley et al. Feb 2002 A1
20020068929 Zvuloni Jun 2002 A1
20020068974 Kuslich et al. Jun 2002 A1
20020077595 Hundertmark et al. Jun 2002 A1
20020082605 Reiley et al. Jun 2002 A1
20020115742 Trieu et al. Aug 2002 A1
20020128638 Chauvel et al. Sep 2002 A1
20020133148 Daniel et al. Sep 2002 A1
20020156483 Voellmicke et al. Oct 2002 A1
20020188299 Reiley et al. Dec 2002 A1
20020188300 Arramon et al. Dec 2002 A1
20030014094 Hammack et al. Jan 2003 A1
20030032929 McGuckin Feb 2003 A1
20030036763 Bhatnagar et al. Feb 2003 A1
20030043963 Yamagami et al. Mar 2003 A1
20030050644 Boucher et al. Mar 2003 A1
20030069522 Jasobsen et al. Apr 2003 A1
20030073979 Naimark et al. Apr 2003 A1
20030130664 Boucher et al. Jul 2003 A1
20030163085 Tanner et al. Aug 2003 A1
20030171744 Leung et al. Sep 2003 A1
20030191489 Reiley et al. Oct 2003 A1
20030195547 Scribner et al. Oct 2003 A1
20030212394 Pearson et al. Nov 2003 A1
20030212395 Woloszko et al. Nov 2003 A1
20030220414 Axen et al. Nov 2003 A1
20030225432 Baptiste et al. Dec 2003 A1
20030233096 Osorio et al. Dec 2003 A1
20040023384 Fukaya Feb 2004 A1
20040023784 Yu et al. Feb 2004 A1
20040024081 Trieu et al. Feb 2004 A1
20040024398 Hovda et al. Feb 2004 A1
20040024409 Sand et al. Feb 2004 A1
20040024410 Olson et al. Feb 2004 A1
20040034384 Fukaya Feb 2004 A1
20040044096 Smith et al. Mar 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040059328 Daniel et al. Mar 2004 A1
20040087936 Stern et al. May 2004 A1
20040087994 Suddaby May 2004 A1
20040092946 Bagga et al. May 2004 A1
20040097612 Rosenberg et al. May 2004 A1
20040111136 Sharkey et al. Jun 2004 A1
20040127987 Evans et al. Jul 2004 A1
20040133208 Weikel et al. Jul 2004 A1
20040138758 Evans et al. Jul 2004 A1
20040153064 Foley et al. Aug 2004 A1
20040153115 Reiley et al. Aug 2004 A1
20040158237 Abboud et al. Aug 2004 A1
20040167561 Boucher et al. Aug 2004 A1
20040167562 Osorio et al. Aug 2004 A1
20040167625 Beyar et al. Aug 2004 A1
20040210231 Broucher et al. Oct 2004 A1
20040215343 Hochschuler et al. Oct 2004 A1
20040220577 Cragg Nov 2004 A1
20040220680 Yamamoto et al. Nov 2004 A1
20040225296 Reiss et al. Nov 2004 A1
20040226479 Lyles et al. Nov 2004 A1
20040230309 Dimauro et al. Nov 2004 A1
20040236186 Chu Nov 2004 A1
20040247644 Bratt et al. Dec 2004 A1
20040267271 Scribner et al. Dec 2004 A9
20050027245 Sachdeva et al. Feb 2005 A1
20050033303 Chappuis et al. Feb 2005 A1
20050038383 Kelley et al. Feb 2005 A1
20050038422 Maurice Feb 2005 A1
20050043737 Reiley et al. Feb 2005 A1
20050055030 Falahee Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050070844 Chow et al. Mar 2005 A1
20050070912 Voellmicke Mar 2005 A1
20050070915 Mazzuca et al. Mar 2005 A1
20050090852 Layne et al. Apr 2005 A1
20050113836 Lozier et al. May 2005 A1
20050119650 Sanders et al. Jun 2005 A1
20050124989 Suddaby Jun 2005 A1
20050143827 Globerman et al. Jun 2005 A1
20050177168 Brunnett et al. Aug 2005 A1
20050177210 Lueng et al. Aug 2005 A1
20050182412 Johnson et al. Aug 2005 A1
20050182413 Johnson et al. Aug 2005 A1
20050187556 Stack et al. Aug 2005 A1
20050199156 Khairoun et al. Sep 2005 A1
20050209557 Carroll et al. Sep 2005 A1
20050216018 Senneii Sep 2005 A1
20050228391 Levy et al. Oct 2005 A1
20050234425 Miller et al. Oct 2005 A1
20050240193 Layne et al. Oct 2005 A1
20050251266 Maspero et al. Nov 2005 A1
20050251267 Winterbottom et al. Nov 2005 A1
20050261683 Veldhuizen et al. Nov 2005 A1
20050283148 Janssen Dec 2005 A1
20050287771 Seamons et al. Dec 2005 A1
20060024348 Engqvist et al. Feb 2006 A1
20060025763 Nelson et al. Feb 2006 A1
20060041033 Bisig et al. Feb 2006 A1
20060052743 Reynolds Mar 2006 A1
20060064101 Arramon Mar 2006 A1
20060074433 McGill et al. Apr 2006 A1
20060084977 Lieberman Apr 2006 A1
20060085009 Truckai et al. Apr 2006 A1
20060100635 Reiley et al. May 2006 A1
20060100706 Shadduck et al. May 2006 A1
20060106392 Embry May 2006 A1
20060106459 Truckai et al. May 2006 A1
20060116689 Albans et al. Jun 2006 A1
20060116690 Pagano Jun 2006 A1
20060122623 Truckai et al. Jun 2006 A1
20060142732 Karmarkar et al. Jun 2006 A1
20060149268 Truckai et al. Jul 2006 A1
20060149281 Reiley et al. Jul 2006 A1
20060156959 Engqvist et al. Jul 2006 A1
20060184106 McDaniel et al. Aug 2006 A1
20060184192 Markworth et al. Aug 2006 A1
20060200121 Mowery Sep 2006 A1
20060206116 Yeung Sep 2006 A1
20060206136 Sachdeva et al. Sep 2006 A1
20060217704 Cockburn et al. Sep 2006 A1
20060217736 Kaneko Sep 2006 A1
20060229625 Truckai et al. Oct 2006 A1
20060229631 Reiley et al. Oct 2006 A1
20060235417 Sala Oct 2006 A1
20060259023 Abboud et al. Nov 2006 A1
20060264819 Fischer et al. Nov 2006 A1
20060264945 Edidin et al. Nov 2006 A1
20060266372 Miller et al. Nov 2006 A1
20060270750 Almen et al. Nov 2006 A1
20060271061 Beyar et al. Nov 2006 A1
20060276797 Botimer Dec 2006 A1
20060276819 Osorio et al. Dec 2006 A1
20060293687 Bogert Dec 2006 A1
20070006692 Phan Jan 2007 A1
20070010845 Gong et al. Jan 2007 A1
20070016130 Leeflang et al. Jan 2007 A1
20070016211 Botimer Jan 2007 A1
20070021769 Scribner et al. Jan 2007 A1
20070043373 Sala Feb 2007 A1
20070055201 Seto et al. Mar 2007 A1
20070055260 Cragg Mar 2007 A1
20070055266 Osorio et al. Mar 2007 A1
20070055275 Schaller Mar 2007 A1
20070055277 Osorio et al. Mar 2007 A1
20070055278 Osorio et al. Mar 2007 A1
20070055279 Sand et al. Mar 2007 A1
20070055281 Osorio et al. Mar 2007 A1
20070055283 Scribner Mar 2007 A1
20070055284 Osorio Mar 2007 A1
20070055285 Osorio et al. Mar 2007 A1
20070055300 Osorio et al. Mar 2007 A1
20070055382 Osorio et al. Mar 2007 A1
20070059281 Moseley et al. Mar 2007 A1
20070067034 Chirico et al. Mar 2007 A1
20070093840 Pacelli Apr 2007 A1
20070114248 Kovac May 2007 A1
20070118142 Krueger et al. May 2007 A1
20070118143 Ralph et al. May 2007 A1
20070142842 Krueger et al. Jun 2007 A1
20070156130 Thistle Jul 2007 A1
20070162042 Dunker Jul 2007 A1
20070173939 Kim et al. Jul 2007 A1
20070185231 Liu Aug 2007 A1
20070197935 Reiley Aug 2007 A1
20070198023 Sand et al. Aug 2007 A1
20070203500 Gordon Aug 2007 A1
20070211563 Devries Sep 2007 A1
20070233146 Henniges et al. Oct 2007 A1
20070260223 Scheibe et al. Nov 2007 A1
20070260257 Phan Nov 2007 A1
20070270876 Kuo et al. Nov 2007 A1
20070276319 Betts Nov 2007 A1
20070282305 Goldfarb et al. Dec 2007 A1
20080004615 Woloszko et al. Jan 2008 A1
20080015664 Podjajsky Jan 2008 A1
20080033422 Turner et al. Feb 2008 A1
20080058725 Scribner et al. Mar 2008 A1
20080058821 Maurer et al. Mar 2008 A1
20080058827 Osorio et al. Mar 2008 A1
20080058840 Albrecht Mar 2008 A1
20080065020 Ralph et al. Mar 2008 A1
20080065087 Osorio et al. Mar 2008 A1
20080065190 Osorio et al. Mar 2008 A1
20080086142 Kohm et al. Apr 2008 A1
20080140079 Osorio et al. Jun 2008 A1
20080183165 Buysee et al. Jul 2008 A1
20080183265 Bly Jul 2008 A1
20080195112 Liu et al. Aug 2008 A1
20080208255 Siegal Aug 2008 A1
20080221608 Betts Sep 2008 A1
20080228192 Beyer et al. Sep 2008 A1
20080249481 Crainich Oct 2008 A1
20080249525 Lee et al. Oct 2008 A1
20080255571 Truckai et al. Oct 2008 A1
20080269766 Justis Oct 2008 A1
20080269796 Reiley et al. Oct 2008 A1
20080287741 Ostrovsky et al. Nov 2008 A1
20080294167 Schumacher et al. Nov 2008 A1
20090076517 Reiley et al. Mar 2009 A1
20090105775 Mitchell et al. Apr 2009 A1
20090131867 Liu et al. May 2009 A1
20090131886 Liu et al. May 2009 A1
20090131945 Liu et al. May 2009 A1
20090131948 Liu May 2009 A1
20090131950 Liu et al. May 2009 A1
20090131986 Lee May 2009 A1
20090182427 Liu et al. Jul 2009 A1
20090198243 Melsheimer Aug 2009 A1
20090264862 Neidert et al. Oct 2009 A1
20090264892 Beyar et al. Oct 2009 A1
20090292289 Sand et al. Nov 2009 A9
20090293687 Nino et al. Dec 2009 A1
20090299282 Lau et al. Dec 2009 A1
20100057087 Cha Mar 2010 A1
20100076476 To et al. Mar 2010 A1
20100082033 Germain Apr 2010 A1
20100114184 Degtyar May 2010 A1
20100121332 Crainich et al. May 2010 A1
20100152724 Marion et al. Jun 2010 A1
20100160922 Liu et al. Jun 2010 A1
20100211076 Germain et al. Aug 2010 A1
20100274270 Patel Oct 2010 A1
20100298832 Lau et al. Nov 2010 A1
20110034884 Pellegrino et al. Feb 2011 A9
20110098701 McIntyre et al. Apr 2011 A1
20110160737 Steffen et al. Jun 2011 A1
20110251615 Truckai et al. Oct 2011 A1
20110295261 Germain Dec 2011 A1
20110295262 Germain et al. Dec 2011 A1
20110301590 Podhajsky et al. Dec 2011 A1
20120065543 Ireland Mar 2012 A1
20120130381 Germain May 2012 A1
20120143298 Just et al. Jun 2012 A1
20120158004 Burger et al. Jun 2012 A1
20120191095 Burger et al. Jul 2012 A1
20120232553 Bloom et al. Sep 2012 A1
20120239049 Truckai Sep 2012 A1
20120265186 Burger et al. Oct 2012 A1
20120277582 Mafi Nov 2012 A1
20120277730 Salahieh Nov 2012 A1
20120330180 Pellegrino et al. Dec 2012 A1
20120330301 Pellegrino et al. Dec 2012 A1
20130006232 Pellegrino Jan 2013 A1
20130006257 Lee Jan 2013 A1
20130041377 Kuntz Feb 2013 A1
20130072941 Tan-Malecki et al. Mar 2013 A1
20130231654 Germain Sep 2013 A1
20130237795 Carr Sep 2013 A1
20130261615 Kramer et al. Oct 2013 A1
20130261621 Kramer et al. Oct 2013 A1
20130345709 Burger et al. Dec 2013 A1
20140135779 Germain May 2014 A1
20140163566 Phan et al. Jun 2014 A1
20140236144 Krueger et al. Aug 2014 A1
20140257046 Steven Sep 2014 A1
20140316413 Burger et al. Oct 2014 A1
20140350542 Kramer et al. Nov 2014 A1
20140371740 Germain et al. Dec 2014 A1
20150216594 Prakash Aug 2015 A1
20150265333 Shin et al. Sep 2015 A1
20150297246 Patel et al. Oct 2015 A1
20150313614 Germain Nov 2015 A1
20160066984 Janssen et al. Mar 2016 A1
20160228131 Brockman et al. Aug 2016 A1
20160310193 Lv et al. Oct 2016 A1
20170095291 Harrington Apr 2017 A1
20170105798 Allison Apr 2017 A1
20180078170 Panescu et al. Mar 2018 A1
20180147006 Purdy May 2018 A1
20180147007 Purdy May 2018 A1
20190357971 Adi et al. Nov 2019 A1
20200022709 Burger et al. Jan 2020 A1
20200078066 Purdy et al. Mar 2020 A1
20200146743 Defosset et al. May 2020 A1
20200390449 Purdy et al. Dec 2020 A1
20210236200 McGregor et al. Aug 2021 A1
20210401496 Purdy et al. Dec 2021 A1
Foreign Referenced Citations (38)
Number Date Country
2785207 Jul 2011 CA
88203061 Nov 1988 CN
2841051 Nov 2006 CN
102500036 Jun 2012 CN
20314010 Jan 2015 DE
1459691 Sep 2004 EP
2004242936 Sep 2004 JP
2008510530 Apr 2008 JP
2008528081 Jul 2008 JP
2008541878 Nov 2008 JP
2010063887 Mar 2010 JP
2011500156 Jan 2011 JP
101342906 Dec 2013 KR
1993004634 Mar 1993 WO
1996013297 May 1996 WO
1996020752 Jul 1996 WO
1997003611 Feb 1997 WO
2002003870 Jan 2002 WO
2003101308 Dec 2003 WO
2005039390 May 2005 WO
2005122938 Dec 2005 WO
2007036815 Apr 2007 WO
2007087400 Aug 2007 WO
2008076330 Jun 2008 WO
2008084479 Jul 2008 WO
2009155319 Dec 2009 WO
2010039894 Apr 2010 WO
2010081187 Jul 2010 WO
2010135602 Nov 2010 WO
2010135606 Nov 2010 WO
2011066465 Jun 2011 WO
2011114602 Sep 2011 WO
2011137357 Nov 2011 WO
2011137377 Nov 2011 WO
2012071464 May 2012 WO
2013147990 Oct 2013 WO
2014093673 Jun 2014 WO
2016183178 Nov 2016 WO
Non-Patent Literature Citations (113)
Entry
US 7,063,700 B2, 06/2006, Michelson (withdrawn)
Notice of Allowance dated Mar. 31, 2021 for U.S. Appl. No. 15/822,864.
Office Action dated May 7, 2021 for U.S. Appl. No. 16/417,502.
International Search Report and Written Opinion dated Apr. 8, 2020 for PCT/US2019/060273.
European Examination Report dated Dec. 19, 2017 for EP13767383.6.
European Search Report dated Jan. 7, 2019 for EP16793433.0.
European Search Report dated Jun. 8, 2017 for EP17154660.9.
European Search Report dated Nov. 15, 2017 for EP09818476.5.
European Search Report dated Nov. 16, 2016 for EP14772615.2.
International Search Report and Written Opinion dated Jan. 9, 2012 for PCT/US2011/034185.
International Search Report and Written Opinion dated Jan. 22, 2009 for PCT/US2008/83698.
International Search Report and Written Opinion dated Feb. 7, 2018 for PCT/US2017/058303.
International Search Report and Written Opinion dated Feb. 21, 2018 for PCT/US2017/063281.
International Search Report and Written Opinion dated Mar. 30, 2018 for PCT/US2017/065328.
International Search Report and Written Opinion dated Apr. 23, 2016 for PCT/US2018/012372.
International Search Report and Written Opinion dated Jul. 20, 2010 for PCT/US2010/035687.
International Search Report and Written Opinion dated Jul. 26, 2011 for PCT/US2011/034628.
International Search Report and Written Opinion dated Aug. 25, 2009 for PCT/US2009/035726.
International Search Report and Written Opinion dated Nov. 20, 2009 for PCT/US2009/059113.
Notice of Allowance dated Jan. 4, 2017 for U.S. Appl. No. 13/302,927.
Notice of Allowance dated Jan. 18, 2017 for U.S. Appl. No. 13/097,998.
Notice of Allowance dated Feb. 21, 2019 for U.S. Appl. No. 14/139,372.
Notice of Allowance dated Apr. 3, 2019 for U.S. Appl. No. 15/349,715.
Notice of Allowance dated Apr. 9, 2014 for U.S. Appl. No. 12/578,455.
Notice of Allowance dated Apr. 23, 2018 for U.S. Appl. No. 13/083,411.
Notice of Allowance dated May 3, 2017 for U.S. Appl. No. 14/815,620.
Notice of Allowance dated May 11, 2018 for U.S. Appl. No. 14/453,427.
Notice of Allowance dated May 26, 2015 for U.S. Appl. No. 13/098,116.
Notice of Allowance dated Aug. 8, 2019 for U.S. Appl. No. 15/836,125.
Notice of Allowance dated Aug. 9, 2019 for U.S. Appl. No. 15/836,241.
Notice of Allowance dated Aug. 24, 2018 for U.S. Appl. No. 15/388,598.
Notice of Allowance dated Sep. 20, 2019 for U.S. Appl. No. 15/793,509.
Notice of Allowance dated Oct. 28, 2016 for U.S. Appl. No. 13/853,397.
Notice of Allowance dated Nov. 8, 2013 for U.S. Appl. No. 12/578,455.
Notice of Allowance dated Nov. 9, 2017 for U.S. Appl. No. 14/815,812.
Notice of Allowance dated Nov. 18, 2016 for U.S. Appl. No. 13/097,998.
Notice of Allowance dated Nov. 25, 2013 for U.S. Appl. No. 12/571,174.
Notice of Allowance dated Nov. 25, 2016 for U.S. Appl. No. 13/853,397.
Notice of Allowance dated Dec. 13, 2018 for U.S. Appl. No. 15/917,454.
Notice of Allowance dated Dec. 28, 2017 for U.S. Appl. No. 15/211,359.
Notice of Allowance dated Aug. 31, 2016 for U.S. Appl. No. 14/887,007.
Office Action dated Jan. 18, 2017 for U.S. Appl. No. 14/815,620.
Office Action dated Jan. 26, 2011 for U.S. Appl. No. 11/941,764.
Office Action dated Jan. 26, 2017 for U.S. Appl. No. 14/815,812.
Office Action dated Feb. 3, 2016 for U.S. Appl. No. 13/853,397.
Office Action dated Feb. 10, 2015 for U.S. Appl. No. 13/083,411.
Office Action dated Feb. 23, 2010 for U.S. Appl. No. 11/941,733.
Office Action dated Feb. 23, 2010 for U.S. Appl. No. 11/941,764.
Office Action dated Mar. 1, 2017 for U.S. Appl. No. 15/211,359.
Office Action dated Mar. 21, 2011 for U.S. Appl. No. 11/941,764.
Office Action dated Mar. 21, 2011 for U.S. Appl. No. 12/029,428.
Office Action dated Apr. 19, 2018 for U.S. Appl. No. 15/388,598.
Office Action dated Apr. 24, 2017 for U.S. Appl. No. 14/453,427.
Office Action dated Apr. 26, 2010 for U.S. Appl. No. 12/029,428.
Notice of Allowance dated May 27, 2021 for U.S. Appl. No. 15/822,944.
Office Action dated Feb. 27, 2013 for U.S. Appl. No. 12/578,455.
Office Action dated Jul. 12, 2016 for U.S. Appl. No. 14/887,007.
Office Action dated Sep. 10, 2013 for U.S. Appl. No. 12/571,174.
Disc-O-Tech confidence Cement System at http://www.disc-o-tech.com/Articles/Article.asp?CategoryID=4&ArticleID=168 accessed, ,Dec. 3, 2007.
Dai, et al., Bone-Particle-Impregnated Bone Cement: an in vivo weight-bearing study, Journal Biomedical Materials Search, vol. 25 ,Jul. 30, 1990 ,141-156.
Hasenwinkel, et al.,“A Novel High-Viscosity, Two-Solution Acrylic Bone Cement: Effect of Chemical Composition on Properties”, J. Biomed Mater. Res. vol. 47, No. 1 ,1999 ,36-45.
Klawitter, et al., Application of Porous Ceramics for the Attachment of Load Bearing Internal Orthopedic Applications, J. Biomed. Mater. Res. Symp., 2(1) ,1972 ,61-229.
Liu, et al., Bone-Particle-Impregnanted Bone Cement: An In Vitro Study, Journal of Biomedical Materials Research, vol. 21 ,1987,247-261.
Park, et al., Biomaterials: An Introduction—Second Edition, Plenum Press ,1992 ,177-178.
Park, et al., The Materials Properties of Bone-Particle Impregnated PMMA, Journal of Biomedical Engineering, vol. 108, 1986, 141-148.
Office Action dated Nov. 27, 2020 for U.S. Appl. No. 15/822,944.
International Search Report and Written Opinion dated Apr. 8, 2020 for PCT/US2019060279.
Notice of Allowance dated Feb. 19, 2020 for U.S. Appl. No. 15/675,315.
European Search Report dated May 29, 2020 for EP17874650.9.
European Search Report dated Jun. 16, 2020 for EP17863626.2.
European Search Report dated Jul. 1, 2020 for EP17878602.6.
Office Action dated Jun. 10, 2020 for U.S. Appl. No. 15/822,944.
Office Action dated Jun. 11, 2020 for U.S. Appl. No. 15/822,864.
Office Action dated May 1, 2009 for U.S. Appl. No. 12/261,987.
Office Action dated May 5, 2010 for U.S. Appl. No. 11/941,764.
Office Action dated May 6, 2019 for U.S. Appl. No. 15/675,315.
Office Action dated May 13, 2009 for U.S. Appl. No. 12/029,428.
Office Action dated May 17, 2010 for U.S. Appl. No. 12/261,987.
Office Action dated May 21, 2014 for U.S. Appl. No. 13/098,116.
Office Action dated May 24, 2012 for U.S. Appl. No. 12/578,455.
Office Action dated May 31, 2016 for U.S. Appl. No. 14/815,620.
Office Action dated Jun. 4, 2018 for U.S. Appl. No. 15/349,715.
Office Action dated Jun. 8, 2009 for U.S. Appl. No. 11/941,764.
Office Action dated Jun. 12, 2009 for U.S. Appl. No. 11/941,733.
Office Action dated Jun. 21, 2013 for U.S. Appl. No. 13/215,098.
Office Action dated Jun. 22, 2018 for U.S. Appl. No. 15/917,454.
Office Action dated Jun. 25, 2015 for U.S. Appl. No. 13/853,397.
Office Action dated Jun. 29, 2018 for U.S. Appl. No. 15/449,591.
Office Action dated Jul. 11, 2017 for U.S. Appl. No. 14/815,812.
Office Action dated Jul. 12, 2010 for U.S. Appl. No. 11/941,764.
Office Action dated Jul. 12, 2017 for U.S. Appl. No. 13/083,411.
Office Action dated Jul. 25, 2011 for U.S. Appl. No. 11/941,733.
Office Action dated Jul. 29, 2013 for U.S. Appl. No. 13/098,116.
Office Action dated Jul. 30, 2013 for U.S. Appl. No. 13/083,411.
Office Action dated Sep. 1, 2010 for U.S. Appl. No. 12/029,428.
Office Action dated Sep. 6, 2017 for U.S. Appl. No. 15/211,359.
Office Action dated Sep. 26, 2017 for U.S. Appl. No. 15/388,598.
Office Action dated Oct. 2, 2018 for U.S. Appl. No. 14/139,372.
Office Action dated Oct. 30, 2018 for U.S. Appl. No. 15/349,715.
Office Action dated Nov. 3, 2008 for U.S. Appl. No. 11/941,764.
Office Action dated Nov. 3, 2008 for U.S. Appl. No. 12/029,428.
Office Action dated Nov. 5, 2008 for U.S. Appl. No. 11/941,733.
Office Action dated Nov. 7, 2019 for U.S. Appl. No. 15/675,315.
Office Action dated Nov. 12, 2013 for U.S. Appl. No. 13/083,411.
Office Action dated Nov. 25, 2016 for U.S. Appl. No. 13/083,411.
Office Action dated Dec. 2, 2009 for U.S. Appl. No. 12/029,428.
Office Action dated Dec. 3, 2012 for U.S. Appl. No. 12/571,174.
Office Action dated Dec. 9, 2009 for U.S. Appl. No. 12/262,064.
Office Action dated Dec. 11, 2009 for U.S. Appl. No. 12/261,987.
Office Action dated Dec. 20, 2019 for U.S. Appl. No. 15/862,441.
Office Action dated Dec. 26, 2019 for U.S. Appl. No. 15/822,864.
Notice of Allowance dated Feb. 7, 2022 for U.S. Appl. No. 16/680,056.
Office Action dated Nov. 29, 2021 for U.S. Appl. No. 16/677,124.
Related Publications (1)
Number Date Country
20200146744 A1 May 2020 US
Provisional Applications (2)
Number Date Country
62757578 Nov 2018 US
62757596 Nov 2018 US